HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression

Journal of Clinical Investigation

Volumn 98, Issue 6, 1996, Pages 1290-1297

  Štefanová, Irena ^a,f   Saville, M Wayne ^a   Peters, Christian ^a   Cleghorn, Farley R ^a   Schwartz, David ^b   Venzon, David J ^a   Weinhold, Kent J ^c   Jack, Noreen ^d   Bartholomew, Courtenay ^d   Blattner, William A ^a   Yarchoan, Robert ^a   Bolen, Joseph B ^e   Horak, Ivan D ^a,g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^e MERCK RESEARCH LABORATORIES   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

HIV; protein tyrosine kinases; signal transduction; T cell receptor; tyrosine phosphorylation

Indexed keywords

BIOCHEMICAL MARKER; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CELL LYSATE; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

EID: 10144250282     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118915     Document Type: Article

References (56)

1. Shearer, G.M., and M. Clerici. 1992. How human immunodeficiency virus ravages the immune system. Curr. Opin. Immunol. 4:463-465.
2. Miedema, F. 1992. Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic. Rev. 3:173-193.
3. Schellekens, P.T.A., M.T.L. Roos, F. De Wolf, J.M.A. Lange, and F. Miedema. 1990. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for AIDS in HIV-1 infected men. J. Clin. Immunol. 10:121-127.
4. van Noesel, C.J.M., R.A. Gruters, F.G. Terpstra, P.T.A. Schellekens, R.A.W. van Lier, and F. Miedema. 1990. Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J. Clin. Invest. 86:293-299.
5. Gruters, R.A., F.G. Terpstra, G.R. De, J.W. Mulder, W.F. De, P.T. Schellekens, L.R. Van, M. Tersmette, and F. Miedema. 1991. Immunological and virological markers in individuals progressing from seroconversion to AIDS. AIDS. 5:837-844.
6. Clerici, M., N.I. Stocks, R.A. Zajac, R.N. Boswell, D.R. Lucey, C.S. Via, and G.M. Shearer. 1989. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seroposilive patients. Independence of CD4+ cell numbers and clinical staging. J. Clin. Invest. 84:1892-1899.
7. Meyaard, L., S.A. Otto, B. Hooibrink, and F. Miedema. 1994. Quantitative analysis of CD4+ T cell function in the course of human immunodeficiency virus infection. Gradual decline of both naive and memory alloreactive T cells. J. Clin. Invest. 94:1947-1952.
8. Fahey, J.L., H. Prince, M. Weaver, J. Groopman, B. Visscher, K. Schwartz, and R. Detels. 1984. Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am. J. Med. 76:95-100.
9. Melbye, M., R.J. Biggar, P. Ebbesen, C. Neuland, J.J. Goedert, V. Faber, I. Lorenzen, P. Skinhoj, R.C. Gallo, and W.A. Blattner. 1986. Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann. Intern. Med. 104:496-500.
10. Dolan, M.J., M. Clerici, S.P. Blatt, C.W. Hendrix, G.P. Melcher, R.N. Boswell, T.M. Freeman, W. Ward, R. Hensley, and G.M. Shearer. 1995. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J. Infect. Dis. 172:79-87.
11. Weiss, A., and D.R. Littman. 1994. Signal transduction by lymphocyte antigen receptor. Cell. 76:263-274.
12. Iwashima, M., B.A. Irving, N.S.C. van Oers, A.C. Chan, and A. Weiss. 1994. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science (Wash. DC). 263:1136-1139.
13. Perlmutter, R.M., S.D. Levin, M.W. Appleby, S.J. Anderson, and I.J. Alberola. 1993. Regulation of lymphocyte function by protein phosphorylation. Annu. Rev. Immunol. 11:451-499.
14. Molina, T.J., K. Kishihara, D.P. Siderovski, E.W. van. A. Narendran, E. Timms, A. Wakeham, C.J. Paige, K.U. Hartmann, A. Veillette, D. Davidson, and T.W. Mak. 1992. Profound block in thymocyte development in mice lacking p56lck. Nature (Lond.). 357:161-164.
15. Appleby, M.W., J.A. Gross, M.P. Cooke, S.D. Levin, X. Qian, and R.M. Perlmutter. 1992. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell. 70:751-763.
16. Stein, P.L., H.M. Lee, S. Rich, and P. Soriano. 1992. pp59fyn mutant mice display differential signaling in thymocytes and peripheral T cells. Cell. 70: 741-750.
17. Negishi, I., N. Motoyama, K. Nakayama, K. Nakayama, S. Senju, S. Halakeyama, Q. Zhang, A. C. Chan, and D. Y. Loh. 1995. Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature (Lond.). 376:435-438.
18. Arpaia, E., M. Shahar, H. Dadi, A. Cohen, and C. M. Roifman. 1994. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell. 76:947-958.
19. Elder, M.E., D. Lin, J. Clever, A.C. Chan, T.J. Hope, A. Weiss, and T.G. Parslow. 1994. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science (Wash. DC). 264:1596-1599.
20. Chan, A.C., T.A. Kadlecek, M.E. Elder, A.H. Filipovich, W.L. Kuo, M. Iwashima, T.G. Parslow, and A. Weiss. 1994. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science (Wash. DC). 264:1599-1601.
21. Center for Disease Control and Prevention. 1992. 1993 revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescent and adults. MMWR (Morbidity and Mortality Weekly Report). 41:1.
22. Kanof, M.E., and P.D. Smith. 1991. Preparation of human mononuclear cell populations and subpopulalions. In Current Protocols in Immunology. Vol. I. (J.E. Coligan, A.M. Kruisbeck, D.H. Margulies, E.M. Shevach, and W. Stroher, editors. John Wiley & Sons, New York. 7.1.1.-7.1.5.
23. Horejsi, V., P. Angelisova, V. Bazil, H. Kristofova, S. Stoyanov, I. Stefanova, P. Hausner, M. Vosecky, and I. Hilgert. 1988. Monoclonal antibodies against human leucocyte antigens. II. Antibodies against CD45 (T200), CD3 (T3), CD43, CD10 (CALLA), transferrin receptor (T9), a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74). Folia Biol. (Praha.). 34:23-34.
24. Stefanova, I., M.L. Corcoran, E.M. Horak, L.M. Wahl, J.B. Bolen, and I.D. Horak. 1993. Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn. J. Biol. Chem. 268:20725-20728.
25. Li, Z.H., S. Mahajan, M.M. Prendergast, J. Fargnoli, X. Zhu, S. Klages, D. Adam, G.L. Schieven, J. Blake, J.B. Bolen, and A.L. Burkhardt. 1992. Cross-linking of surface immunoglobulin activates src-related tyrosine kinases in WEHI 231 cells. Biochem. Biophys. Res. Commun. 187:1536-1544.
26. Burkhardt, A.L., B. Stealey, R.B. Rowley, S. Mahajan, M. Prendergast, J. Fargnoli, and J.B. Bolen. 1994. Temporal regulation of non-transmembrane protein tyrosine kinase enzyme activity following T cell antigen receptor engagement. J. Biol. Chem. 269:23642-23647.
27. Bolen, J.B., P.A. Thompson, E. Eiseman, and I.D. Horak. 1991. Expression and interactions of the Src family of tyrosine protein kinases in T lymphocytes. Adv. Cancer Res. 57:103-149.
28. Perlmutter, R.M., J.D. Marth, D.B. Lewis, R. Peet, S.F. Ziegler, and C.B. Wilson. 1988. Structure and expression of lck transcripts in human lymphoid cells. J. Cell. Biochem. 38:117-126.
29. Wain-Hobson, S., J.P. Vartanian, M. Henry, N. Chenciner, R. Cheynier, S. Delassus, L.P. Martins, M. Sala, M.T. Nugeyre, D. Guetard, D. Klatzmann, C. Gluckman, W. Rozenbaum, F. Barre-Sinoussi, and L. Montagnier. 1991. LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science (Wash. DC). 252:961-965.
30. Johnson, V.A., and R.E. Byington. 1990. Quantitative assays for virus infectivity. Stockton Press, New York. 71-76.
31. June, C.H., M.C. Fletcher, J.A. Ledbetter, and L.E. Samelson. 1990. Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J. Immunol. 144:1591-1599.
32. Straus, D.B., and A. Weiss. 1992. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell. 70:585-593.
33. Cayota, A., F. Vuillier, J. Siciliano, and G. Dighiero. 1994. Defective protein tyrosine phosphorylation and altered levels of p59fyn and p56lck in CD4 T cells from HIV-1 infected patients. Int. Immunol. 6:611-621.
34. Bolen, J.B. 1993. Nonreceptor tyrosine protein kinases. Oncogene. 8: 2025-2031.
35. Abraham, N., and A. Veillette. 1990. Activation of p56lck through mutation of a regulatory carboxy-terminal tyrosine residue requires intact sites of autophosphorylation and myristylation. Mol. Cell. Biol. 10:5197-5206.
36. Gervais, F.G., L. Chow, J.M. Lee, P.E. Branton, and A. Veillette. 1993. The SH2 domain is required for stable phosphorylation of p56lck at tyrosine 505, the negative regulatory site. Mol. Cell. Biol. 13:7112-7121.
37. Droge, W., O.K. Schulze, S. Mihm, D. Galter, H. Schenk, H.P. Eck, S. Roth, and H. Gmunder. 1994. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 8:1131-1138.
38. Staal, F.J., M. Roederer, D.M. Israelski, J. Bubp, L.A. Mole, D. McShane, S.C. Deresinski, W. Ross, H. Sussman, P.A. Raju, M.T. Anderson, W. Moore, S.W. Ela, L.A. Herzenberg, and L.A. Herzenberg. 1992. Intracellular glulathione levels in T cell subsets decrease in HIV-infected individuals. AIDS Res. Hum. Retroviruses. 8:305-311.
39. Aukrust, P., A.M. Svardal, F. Muller, B. Lunden, R.K. Berge, P.M. Ueland, and S.S. Froland. 1995. Increased Levels of Oxidized Glutathione in CD4+ Lymphocytes Associated With Disturbed Intracellular Redox Balance in Human Immunodeficiency Virus Type 1 Infection. Blood. 86:258-267.
40. Kanner, S.B., T.J. Kavanagh, A. Grossmann, S.L. Hu, J.B. Bolen, P.S. Rabinovitch, and J.A. Ledbetter. 1992. Sulfhydryl oxidation down-regulates T-cell signaling and inhibits tyrosine phosphorylation of phospholipase C gamma 1. Proc. Natl. Acad. Sci. USA. 89:300-304.
41. Staal, F.J., M.T. Anderson, G.E. Staal, L.A. Herzenberg, C. Gitler, and L.A. Herzenberg. 1994. Redox regulation of signal transduction: tyrosine phosphorylation and calcium influx. Proc. Natl. Acad. Sci. USA. 91:3619-3622.
42. Meister, A. 1988. Glutathione metabolism and its selective modification. J. Biol. Chem. 263:17205-17208.
43. Hamilos, D.L., and H.J. Wedner. 1985. The role of glutathione in lymphocyte activation. I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-1-one by nuclear size transformation. J. Immunol. 135:2740-2747.
44. Droge, W., G.C. Pottmeyer, H. Schmidt, and S. Nick. 1986. Glutathione augments the activation of cytotoxic T lymphocytes in vivo. Ummunobiology. 172:151-156.
45. Suthanthiran, M., M.E. Anderson, V.K. Sharma, and A. Meister. 1990. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc. Natl. Acad. Sci. USA. 87:3343-3347.
46. Eck, H.P., H. Gmunder, M. Hartmann, D. Petzoldt, V. Daniel, and W. Droge. 1989. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol. Chem. Hoppe Seyler. 370:101-108.
47. Buhl, R., H.A. Jaffe, K.J. Holroyd, F.B. Wells, A. Mastrangeli, C. Saltini, A.M. Cantin, and R.G. Crystal. 1989. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 2:1294-1298.
48. Staal, F.J., M. Roederer, L.A. Herzenberg, and L.A. Herzenberg. 1992. Glutathione and immunophenotypes of T and B lymphocytes in HIV-infected individuals. Ann. NY Acad. Sci. 651:453-463.
49. Armstrong, J.A., and R. Horne. 1984. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet. 2:370-372.
50. Pantaleo, G., C. Graziosi, J.F. Demarest, L. Butini, M. Montroni, C.H. Fox, J.M. Orenstein, D.P. Kotler, and A.S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (Lond.). 362:355-358.
51. Cheynier, R., S. Henrichwark, F. Hadida, E. Pelletier, E. Oksenhendler, B. Autran, and H.S. Wain. 1994. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell. 78:373-387.
52. Sheppard, H.W., W. Lang, M.S. Ascher, E. Vittinghoff, and W. Winkelstein. 1993. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7:1159-1166.
53. Buchbinder, S.P., M.H. Katz, N.A. Hessol, P.M. O'Malley, and S.D. Holmberg. 1994. Long-term HIV-1 infection without immunologic progression. AIDS. 8:1123-1128.
54. Easterbrook, P.J. 1994. Non-progression in HIV infection. AIDS. 8: 1179-1182.
55. Schwartz, D., U. Sharma, M. Busch, K. Weinhold, T. Matthews, J. Lieberman, D. Birx, H. Farzedagen, J. Margolick, T. Ouinn, B. Davis, O. Bagasra, R. Pomerantz, and R. Viscidi. 1994. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res. Hum. Retroviruses. 10:1703-1711.
56. Mulder, J., N. McKinney, C. Christopherson, J. Sninsky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.